

**Minutes of the Lancashire Medicines Management Group Meeting
held on Thursday 14th March 2013 at Preston Business Centre**

PRESENT:

Dr Tony Naughton (TN) Louise Winstanley (LW)	Chair CCG Lead Pharmacist and Prescribing Support Team Manager	NHS Fylde & Wyre CCG NHS Fylde and Wyre CCG
Dr Manjit Jandu (MJ) Lisa Rogan (LR)	GP Lead Head of Medicines Commissioning (designate)	NHS Greater Preston CCG NHS East Lancashire and Blackburn with Darwen CCGs
Dr Li Kam Wa (LWK)	Consultant General Medicines/ D & T Chair	Blackpool teaching Hospitals
Pauline Bourne (PB)	Senior Pharmacist Medicines Management	University Hospitals of Morecambe Bay
Dr Robert Mitchell (RM) Dr Kamlesh Sidhu (KS) Gareth Price (GP)	Clinical Lead & Board Member GP Prescribing Lead Chief Pharmacist	NHS Fylde & Wyre CCG NHS Lancashire North CCG Lancashire Teaching Hospitals NHS Foundation Trust
Christine Woffindin (CW) Dr Jane Lofthouse (JL)	Medicines Information Manager GP Lead	East Lancs Hospital Trust NHS Chorley and South Ribble CCG
Nicola Baxter		NHS West Lancashire CCG

IN ATTENDANCE:

Elaine Johnstone (EJ)	Senior Executive – Medicines Management (Designate)	Lancashire Commissioning Support Unit
Catherine Harding (CH) Brent Horrell (BH)	Head of Medicines Management Head of Medicines Commissioning (Designate)	NHS East Lancashire Lancashire Commissioning Support Unit
Julie Lonsdale (JL)	Head of Medicines Commissioning (Designate)	Lancashire Commissioning Support Unit
Cath Lawless	PA To head of Medicines Management	NHS Blackburn with Darwen
Graham Webb	Administrative Assistant	Lancashire CSU

ITEM	SUMMARY OF DISCUSSION	ACTION
2013/021	WELCOME AND INTRODUCTIONS	
2013/022	APOLOGIES: Apologies were received from: Alastair Gibson, Dr O'Donnell, Dr Muzaffar, Eric Bonsell, Melanie Preston, Neil Fletcher, Dr Sakthi Karunanithi, Dr Muzzafar, Cath Fewster, David Shakespeare, Linda Bracewell, Jim Gardner, Mark Collins, Kam Mom, and George Nasmyth	
2013/023	DECLARATIONS OF INTEREST PERTINENT TO THE AGENDA There were no declarations of interest.	

2013/024	<p>DECLARATION OF ANY OTHER URGENT BUSINESS</p> <p>Item 2013/033 – Presenter of item changed to Lesley Davey, who will attend only to present the paper.</p> <p>AOB: LW asked for a discussion on the Newer Oral Anticoagulant Agents (NOACs) to be placed on the agenda before the start of the agenda items.</p>	
2013/025	<p>MINUTES OF THE MEETINGS HELD ON 14th FEBRUARY 2013</p> <p>The minutes were accepted as a true record.</p>	
2013/026	<p>MATTERS ARISING: ACTION SHEET FROM THE 14th FEBRUARY MEETING</p> <p>Page 2 - 2012/041 POLICY FOR THE PRESCRIBING OF VITAMINS, MINERAL, SUPPLEMEMNTS, HERBAL AND HOMEOPATHIC MEDICINES WITHOUGH A PRODUCT LICENCE - BH reported that he had received positive recommendations with regards to the various organisations adopting the policy, but had not heard from all LMMG member organisations. ACTION: LMMG member organisations to notify BH whether they are to adopt the policy.</p> <p>Page 4 – BENEFITS PROPSAL FOR HIGH COST DRUGS – ACTION: CH to update paper and e-mail out for comments</p> <p>Page 5 – LANCASHIRE MEDICINES MANAGEMENT HORIZON SCANNING 2013/14</p> <ul style="list-style-type: none"> • COPD treatment guideline group <p>There was some discussion regarding the proposed working arrangements for the COPD treatment guideline development group with concern expressed that the work should not re-invent what was already available, but equally should engage relevant, local clinical opinion. EJ said that a small group to discuss National Guidelines would be of benefit and to use key contacts from clinical groups to help support this piece of work going forward. It was noted that the response to a request for contacts clinical leads had been poor. ACTION: BH to send out e-mail request for contacts again as some members of the group had not received the request.</p> <p>AOB: NOACs – LW said that she had received a number of concerns from GPs around the prescribing of NOACs and implementation of the guidelines, and asked if other organisations had received any complaints of the same nature. Group members said that they had not received any complaints from GPs, so LW agreed to seek local resolution.</p>	<p>BH</p> <p>CH</p> <p>BH</p>
2013/027	<p>AFLIBERCEPT BRIEFING REPORT - CH reported that Richard Lee has not been able to meet with lead with ophthalmologists to consider Aflibercept due to their clinic commitments. ACTION: RL to prepare a draft policy for consultation, based on work from North East England.</p>	Richard Lee / BH
2013/028	<p>TRAFFIC LIGHT DRUG CLASSIFICATION – Approval was given by the group for the patient information leaflet and poster. CH highlighted the need for a further piece of work to standardise the amber drug classification system</p>	

	across Lancashire and suggested this could come back to the April meeting. EJ suggested that an acknowledgement to the work of NHS Leeds be included. ACTION: CH to add acknowledgement to NHS Leeds	CH
2013/029	GUIDELINES FOR GOOD PRESCRIBING IN PRIMARY CARE Comments from the group were supportive of the guidance, indicating that it would prove useful to GP practices. A number of changes were agreed. ACTION: CH Pages 3, 5 and 6 all have various errors to be amended, and also to add in Repeat Dispensing – Pharmacies to dispense medicines that are only requested. Review date to be changed to 2016.	CH
2013/030	LANCASHIRE MEDICINES MANAGEMENT GROUP APPLICATION CRITERIA EJ asked the group to comment on the proposed criteria for sending items to the group. After discussion it was agreed to make the following amendments: <ul style="list-style-type: none"> • No 1 and 7 should be come No 1 and 2 and form the main threshold criteria. • No 4 – To reword to “could potentially create a significant cost pressure”. • To add a new criterion of “could potentially release significant savings”. • No 7 – To add in NICE guidance <i>for the proposed indication</i> and change the timescale from 3 months to 6 months. • To add in an additional criterion of – “Where there is a need for clarification of NICE guidance”. • Numbers 8/9/10 – To be removed from criteria and changed to footnotes. ACTION: EJ to update criteria and to send out. Also to add to the LMMG application form.	EJ
2013/031	LANCASHIRE MEDICINES MANAGEMENT GROUP – NEW MEDICATION REQUESTS WORK PLAN BH asked for comments from the group as to the areas of work to be undertaken by the Group. The following decisions were agreed: <ul style="list-style-type: none"> • Omacor – This guidance was currently being drafted and would come to the April meeting • Rheumatology Anti TNF –There is a meeting with the rheumatology alliance on the 19th of April, it was agreed that this would be picked up at that meeting. • Perampanel – the New Medicine Review is in the process of being drafted and will be circulated to member organisations once complete. • Vitamin D – Process Updated – Comments from the group that the guidance prepared by Hillary Smith although was very good was far too long for use in practices. LW said that she had prepared a shorter version. ACTION: LW to share short version. • Eplerenone – It was agreed that a short review would be completed looking at the license extension of eplerenone. • Combodart – A short review of Combodart would be completed. • Tocilizumab – There is a meeting with the rheumatology alliance on the 19th of April, it was agreed that this would be picked up at that meeting. • Linacotide – This would be prioritised for review. 	LW

	<ul style="list-style-type: none"> • Tafamidis – On-going • Dapagliflozin – This would be prioritised for review. • Insulin Degludec – Cost pressure issues where raised by the group. • Pegloticase and Canakinumab – Position statements from NHS East Lancashire to be brought to the next meeting for consideration by LMMG. • Nebulised Amoxicillin – Salford trialling- To be taken off for local decision. • Acidinium – To be prioritised for review • Aquamax – Low priority, no plans to review <p>BH asked for key priorities from the group – LR stated that her priorities would be: Dapagliflozin, Acidinium, Omalizumab. BH asked other members to email the CSU with key priorities.</p>	
2013/033	<p>REPEAT PRESCRIPTION REQUEST AUDIT REPORT</p> <p>Lesley Davey outlined the work carried out at three East Lancashire GP practices to identify the potential for medicines waste and asked the group to consider options to take the work forward, including the establishment of a sub-group to consider in more detail the issues. TN queried whether the LMMG was the appropriate group for discussion of this business and suggested that perhaps this paper should have been given to CCGs for their internal discussion across the patch. CH sought to add clarification by briefly stating that the paper had previously been considered by the Lancashire Pharmacy Transformation Board.</p> <p>ACTION: Linda Bracewell to be invited to lead a further discussion on the implications of this work for the LMMG at the next meeting.</p>	LB
2013/032	<p>POLICY FOR INTERVENTIONS FOR HYPERHYDROSIS</p> <p>An earlier draft of the policy had been circulated to the group membership for comment. Presented with the papers was a further iteration of the policy document for consideration. KS queried its inclusion in the agenda for the meeting. EJ clarified that the relevance was in relation to the commissioning of botulinum toxin, a high cost drug for which CCGs would be responsible.</p> <p>ACTION: LMMG members to submit comments of policy to Martin Smith at NHS East Lancashire martin.smith4@eastlancspct.nhs.uk .</p>	ALL
2013/034	<p>LUCENTIS FOR DIABETIC MACULAR OEDEMA</p> <p>EJ explained to the group that this was a recent piece of NICE guidance which required implementation across Lancashire. The manufacturer had been contacting CCGs with offers of support, and it was suggested that this be co-ordinated via the CSU. It was noted there could be service redesign implications around developing provider capacity to implement this guidance across Lancashire. This was agreed as a way forward.</p> <p>ACTION: EJ to speak to the industry. CCGs invited to refer any pharmaceutical industry contacts to the CSU.</p>	EJ
2013/035	<p>CLOPIDOGREL LEAFLET</p> <p>LR presented this version of the leaflet which had been updated following previous comments. The leaflet was approved though a persistent spelling mistake was noted.</p> <p>ACTION: LR to inform the cardiac network that the leaflet is approved subject to correction of the spelling error.</p>	LR

2013/042	<p>DATE AND TIME OF NEXT MEETING Thursday 11th April 2013 - 9.30 – 11.30 A.M. Meeting Room 2, Preston Business Centre. Link to venue directions http://www.lancsteachinghospitals.nhs.uk/trust-information/find-us/directions-to-smrc.html</p>	
	<p>FUTURE MEETINGS Future meeting dates would be scheduled for the 2nd Thursday of the month at 9.30am (Preston Business Centre)</p> <p>9th May (2013) 13th June (2013) 11th July (2013) 8th August (2013) 12th September (2013) 10th October (2013) 14th November (2013) 12th December (2013)</p>	

**ACTION SHEET FROM THE
LANCASHIRE MEDICINES MANAGEMENT GROUP**

THURSDAY 14th MARCH 2013

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2013/026	<p>MATTERS ARISING: ACTION SHEET FROM THE 14th FEBRUARY MEETING</p> <p>Page 2 - 2012/041 POLICY FOR THE PRESCRIBING OF VITAMINS, MINERAL, SUPPLEMENTS, HERBAL AND HOMEOPATHIC MEDICINES WITHOUT A PRODUCT LICENCE - ACTION: Member organisations to notify the CSU whether they are to adopt the policy.</p> <p>Page 4 – BENEFITS PROPOSAL FOR HIGH COST DRUGS – ACTION: CH to update paper and e-mail out for comment</p> <p>Page 5 – COPD TREATMENT GUIDELINE GROUP– ACTION: BH to send out e-mail request for contacts again as members of the group had not received the request.</p>	<p style="text-align: center;">All</p> <p style="text-align: center;">CH</p> <p style="text-align: center;">BH</p>	<p style="text-align: center;">March 13</p> <p style="text-align: center;">March 13</p> <p style="text-align: center;">March 13</p>
2013/027	<p>AFLIBERCEPT BRIEFING REPORT - ACTION: RL to prepare a draft policy for consultation. Based on work from North East England</p>	RL	March 13
2013/029	<p>GUIDELINES FOR GOOD PRESCRIBING IN PRIMARY CARE – ACTION: CH Pages 3, 5 and 6 all have various errors to be amended, and also to add in Repeat Dispensing – Pharmacies to dispense medicines that are only requested. Review date to be changed to 2016.</p>	CH	March 13
2013/30	<p>LANCASHIRE MEDICINES MANAGEMENT GROUP APPLICATION CRITERIA – EJ to alter criteria and send out to members. Also to add to LMMG application form</p>	EJ	March 13
2013/033	<p>REPEAT PRESCRIPTION AUDIT REPORT ACTION: Linda Bracewell to lead discussion on this report at the next meeting.</p>	LB	March 13
2013/032	<p>POLICY FOR INTERVENTIONS FOR HYPERHYDROSIS – ACTION: Group to submit comments on policy to Martin Smith at NHS East Lancashire.</p>	ALL	March 13
2013/033	<p>LUCENTIS FOR DIABETIC MACULAR OEDEMA – ACTION: EJ to speak to the industry. CCG's to refer.</p>	EJ	March 13
2013/035	<p>CLOPIDOGREL LEAFLET– ACTION: LR to inform cardiac network of approval subject to correction of spelling mistake</p>	LR	March 13